Generics in chronic myeloid leukemia: current arguments for and against and the established evidence

References

• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S. The chronic leukemias. In: Goldman L, Schafer A, Arend W, et al. editors. Cecil Medicine. 24 edition. Elsevier Saunders; Philadelphia, PA: 2012. p. 1209-18
   Google Scholar
• Eskazan AE, Elverdi T, Yalniz FF, et al. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121(22):4439-42
   PubMed Web of Science ®Google Scholar
• Kerr D. Generic drugs: their role in better value cancer care. Ann Oncol 2013;24(Suppl 5):v5
   Google Scholar
• Mathews V. Generic Imatinib: the real-deal or just a deal? Leuk Lymphoma 2014. [ Epub ahead of print]
   Google Scholar
• Parrillo-Campiglia S, Ercoli MC, Umpierrez O, et al. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther 2009;31(10):2224-32
   PubMedGoogle Scholar
• Mattar M. Failure of copy imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010;91(1):104-6
   PubMedGoogle Scholar
• Gogtay J, Chahchad S, Jadhav S, et al. Response to the case report by Mattar: generic imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int J Hematol 2010;92(5):772-3
   PubMedGoogle Scholar
• Asfour IA, Elshazly SA. Changing therapy from Glivec to a “copy” imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009;2:9342
   PubMedGoogle Scholar
• Alwan AF, Matti BF, Naji AS, et al. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back. Leuk Lymphoma 2014. [ Epub ahead of print]
   Google Scholar
• Saavedra D, Vizcarra F. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in the chronic phase (CML-CP): a case series on an escalating issue impacting patient safety. Leuk Lymphoma 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Baslar Z. Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients. European Hematology Association Press Releases. Available from: www.ehaweb.org/news/press/eha-press-releases/article/81/do-generics-of-imatinib-jeopardize-patient-safety-for-the-sake-of-saving-money-an-experience-in-turkish-patients
   Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013;122(6):872-84
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11(11):1029-35
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122(4):515-22
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Ayer M, Kantarcioglu B, et al. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. Br J Haematol 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Razmkhah F, Razavi M, Zaker F, et al. Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia. Lab Med 2010;41:547-50
   Web of Science ®Google Scholar
• Khoshnaw N, Francis B, Safar BM, et al. Cytogenetic response in chronic myeloid leukaemia patients treated with imatinib mesylate homolog-drugs: 6 year’s transitional study. J Cancer Ther 2014;5:453-9
   Google Scholar
• Malhotra H, Sharma P, Bhargava S, et al. Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Leuk Lymphoma 2014. [ Epub ahead of print]
   Google Scholar
• Eskazan AE, Ar MC, Soysal T. The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety? Leuk Lymphoma 2014. [ Epub ahead of print]
   Google Scholar